Renal cell carcinoma · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | aggressive |
|---|---|
| Linked regimen | None |
| ID | IND-HLRCC-CARRIER-INTENSIFIED |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | DIS-RCC |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
STUB — v0.2-B HLRCC intensified-track. §15.2 C4 ≥2-tracks invariant.
Used By
No reverse references found in the YAML corpus.